Semaglutide significantly resolves MASH and reduces liver fat, but anti-fibrotic efficacy is stage-dependent
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a substantial global health burden, often leading to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Despite its high prevalence, effective pharmacological therapies for MASH remain limited. Semaglutide, a GLP-1 receptor agonist, has shown promise in metabolic and hepatic benefits, but its specific action on hepatic fibrosis has been inconsistently reported, necessitating updated evidence.
Study Design
This systematic review and meta-analysis synthesized data from 10 studies involving n=1908 participants to evaluate the efficacy and safety of semaglutide in MASH. Following PRISMA guidelines, researchers searched databases through January 8, 2026. Primary outcomes included histological MASH resolution and fibrosis improvement (defined as ≥1 stage improvement). Secondary outcomes assessed changes in liver stiffness via radiological methods and various biochemical markers, with safety profiles also analyzed.
Results
Semaglutide demonstrated a significant improvement in MASH resolution without worsening fibrosis.
MASH resolution was significantly higher with semaglutide, showing an odds ratio (OR) of 3.48 (95% CI: 2.68-4.53; p < .00001) compared to control groups. However, the pooled analysis for fibrosis improvement (≥1 stage) did not reach statistical significance, with an OR of 1.17 (95% CI: 0.49-2.80; p = .72). Radiologically, semaglutide significantly reduced liver stiffness by a mean difference (MD) of -1.25 kPa (95% CI: -2.18 to -0.32; p = .009) and increased the relative liver fat reduction of ≥30% (OR 7.16; 95% CI: 3.08-16.64; p < .00001). Significant reductions were also observed in biochemical markers such as
AST,ALT, and total cholesterol. Regarding safety, semaglutide was associated with a higher risk of gastrointestinal-related adverse events (RR = 1.83; 95% CI: 1.20-2.79), but no significant difference was found in the risk of serious adverse events (RR = 1.07; 95% CI: 0.82-1.39).
Key Findings
- Semaglutide significantly improved MASH resolution (OR 3.48; p < .00001).
- Fibrosis improvement (≥1 stage) was not statistically significant (OR 1.17; p = .72).
- Liver stiffness was reduced by -1.25 kPa (MD; p = .009).
- Relative liver fat reduction of ≥30% increased (OR 7.16; p < .00001).
- Higher risk of GI-related adverse events (RR = 1.83) but no increase in serious adverse events.
Why It Matters
This meta-analysis solidifies semaglutide's role as a potent therapeutic agent for metabolic dysfunction-associated steatohepatitis (MASH), particularly in achieving histological resolution and reducing hepatic fat. Clinicians and biohackers should consider semaglutide as a primary intervention for early-stage MASLD/MASH, given its strong efficacy in resolving steatohepatitis and improving key imaging and biochemical markers. While its anti-fibrotic effects appear limited to non-cirrhotic stages and current trial durations, its overall benefits for liver health are substantial. This reinforces its utility in managing the metabolic components of liver disease, potentially preventing progression to more advanced fibrosis if initiated earlier.
semaglutide
masld
mash
liver-fat
fibrosis
meta-analysis